Viremia and Drug Resistance Among HIV-1 Patients on Antiretroviral Treatment: a Cross-sectional Study in Soweto, South Africa

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2010 May 11

PMID 20453629

Citations 72

Authors

Ziad El-Khatib

Anna Mia Ekstrom

Johanna Ledwaba

Lerato Mohapi

Fatima Laher

Alan Karstaedt

Salome Charalambous

Max Petzold

David Katzenstein

Lynn Morris

Affiliations

Soon will be listed here.

Abstract

Background: We assessed risk factors for viremia and drug resistance among long-term recipients of antiretroviral therapy (ART) in South Africa.

Methods: In 2008, we conducted a cross-sectional study among patients receiving ART for 12 months or more. Genotypic resistance testing was performed on individuals with a viral load higher than 400 RNA copies/ml. Multiple logistic regression analysis was used to assess associations.

Results: Of 998 participants, 75% were women with a median age of 41 years. Most (64%) had been on treatment for more than 3 years. The prevalence of viremia was 14% (n = 139): 12% (102/883) on first-line [i.e. nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen] and 33% (37/115) on second-line (i.e. protease inhibitor (PI)-based regimen) ART. Of viremic patients, 78% had drug resistance mutations. For NRTIs, NNRTIs and PIs, the prevalence of mutations was 64, 81 and 2%, respectively, among first-line failures and 29, 54 and 6%, respectively, among second-line failures. M184V/I, K103N and V106A/M were the most common mutations. Significant risk factors associated with viremia on first-line regimen included concurrent tuberculosis treatment [odds ratio (OR) 6.4, 95% confidence interval (CI) 2.2-18.8, P < 0.01] and a recent history of poor adherence (OR 2.7, 1.3-5.6, P = 0.01). Among second-line failures, attending a public clinic (OR 4.6, 95% CI 1.8-11.3, P < 0.01) and not having a refrigerator at home (OR 6.7, 95% CI 1.2-37.5, P = 0.03) were risk factors for virological failure.

Conclusion: Risk factors for viral failure were line regimen dependent. Second-line ART recipients had a higher rate of viremia, albeit with infrequent PI drug resistance mutations. Measures to maintain effective virologic suppression should include increased adherence counseling, attention to concomitant tuberculosis treatment and heat-stable formulations of second-line ART regimens.

Citing Articles

Comparing pill counts and patient self-reports versus DBS tenofovir concentrations as ART adherence measurements with virologic outcomes and HIV drug resistance in a cohort of adolescents and young adults failing ART in Harare, Zimbabwe.

Mtisi T, Kouamou V, Morse G, Dzinamarira T, Ndhlovu C J Infect Public Health. 2024; 17(9):102500.

PMID: 39173560 PMC: 11393767. DOI: 10.1016/j.jiph.2024.102500.

A multidisciplinary approach for people with HIV failing antiretroviral therapy in South Africa.

Juta P, Jansen van Vuuren J, Mbaya K South Afr J HIV Med. 2024; 25(1):1579.

PMID: 39113780 PMC: 11304356. DOI: 10.4102/sajhivmed.v25i1.1579.

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.

Asare K, Lewis L, van der Molen J, Sookrajh Y, Khubone T, Moodley P Open Forum Infect Dis. 2023; 10(12):ofad583.

PMID: 38045558 PMC: 10691652. DOI: 10.1093/ofid/ofad583.

Spatiotemporally Comparative Analysis of HIV, Pulmonary Tuberculosis, HIV-Pulmonary Tuberculosis Coinfection in Jiangsu Province, China.

Wu Z, Fu G, Wen Q, Wang Z, Shi L, Qiu B Infect Drug Resist. 2023; 16:4039-4052.

PMID: 37383602 PMC: 10296641. DOI: 10.2147/IDR.S412870.

Spatiotemporal Variation and Predictors of Unsuppressed Viral Load among HIV-Positive Men and Women in Rural and Peri-Urban KwaZulu-Natal, South Africa.

Soogun A, Kharsany A, Zewotir T, North D, Ogunsakin E, Rakgoale P Trop Med Infect Dis. 2022; 7(9).

PMID: 36136643 PMC: 9502339. DOI: 10.3390/tropicalmed7090232.

References

Johannessen A, Naman E, Kivuyo S, Kasubi M, Holberg-Petersen M, Matee M . Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. 2009; 9:108. PMC: 2713244. DOI: 10.1186/1471-2334-9-108. View

Bangsberg D, Ware N, Simoni J . Adherence without access to antiretroviral therapy in sub-Saharan Africa?. AIDS. 2005; 20(1):140-1. DOI: 10.1097/01.aids.0000196168.50303.31. View

Murillo W, de Rivera I, Parham L, Jovel E, Palou E, Karlsson A . Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med. 2009; 11(2):95-103. DOI: 10.1111/j.1468-1293.2009.00747.x. View

Nachega J, Stein D, Lehman D, Hlatshwayo D, Mothopeng R, Chaisson R . Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004; 20(10):1053-6. DOI: 10.1089/aid.2004.20.1053. View

Nel J, Dlamini S, Meintjes G, Burton R, Black J, Davies N . Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. South Afr J HIV Med. 2020; 21(1):1115. PMC: 7564911. DOI: 10.4102/sajhivmed.v21i1.1115. View

Reynolds N, Sun J, Nagaraja H, Gifford A, Wu A, Chesney M . Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr. 2007; 46(4):402-9. DOI: 10.1097/qai.0b013e318158a44f. View

Rosenblum M, Deeks S, van der Laan M, Bangsberg D . The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009; 4(9):e7196. PMC: 2747009. DOI: 10.1371/journal.pone.0007196. View

Westreich D, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P . Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009; 48(11):1617-23. PMC: 2787193. DOI: 10.1086/598977. View

Wallis C, Mellors J, Venter W, Sanne I, Stevens W . Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2009; 53(4):480-4. DOI: 10.1097/QAI.0b013e3181bc478b. View

10.

Martinson N, Mohapi L, Bakos D, Gray G, McIntyre J, Holmes C . Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009; 50(3):327-30. PMC: 3080749. DOI: 10.1097/QAI.0b013e3181958546. View

11.

Nachega J, Mills E, Schechter M . Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010; 5(1):70-7. DOI: 10.1097/COH.0b013e328333ad61. View

12.

Ford N, Mills E, Calmy A . Rationing antiretroviral therapy in Africa--treating too few, too late. N Engl J Med. 2009; 360(18):1808-10. DOI: 10.1056/NEJMp0902820. View

13.

Hoffmann C, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson R . Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009; 49(12):1928-35. PMC: 2789416. DOI: 10.1086/648444. View

14.

Lawn S, Kranzer K, Wood R . Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009; 30(4):685-99, viii. PMC: 2887494. DOI: 10.1016/j.ccm.2009.08.010. View

15.

Maldonado F, Biot M, Roman F, Masquelier C, Anapenge M, Bastos R . Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg. 2008; 103(6):607-12. DOI: 10.1016/j.trstmh.2008.07.014. View

16.

Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A . Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS. 2002; 16(7):1039-44. DOI: 10.1097/00002030-200205030-00010. View

17.

Ramadhani H, Thielman N, Landman K, Ndosi E, Gao F, Kirchherr J . Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007; 45(11):1492-8. DOI: 10.1086/522991. View

18.

Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L . HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008; 24(11):1449-54. PMC: 8884175. DOI: 10.1089/aid.2008.0180. View

19.

Wallis C, Mellors J, Venter W, Sanne I, Stevens W . Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat. 2011; 2011:769627. PMC: 3066558. DOI: 10.1155/2011/769627. View

20.

Rosen S, Fox M, Gill C . Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4(10):e298. PMC: 2020494. DOI: 10.1371/journal.pmed.0040298. View